Neuropsychological characteristics of mild cognitive impairment subgroups

O L Lopez1, J T Becker, W J Jagust

  • 1Department of Neurology, University of Pittsburgh, School of Medicine, PA 15213, USA. lopezol@upmc.edu

Abstract

Insights

Mild cognitive impairment (MCI) presents in distinct subgroups. The amnestic type shows memory deficits, while the multiple cognitive deficits type exhibits broader impairments, including non-memory domains.

Area of Science:

  • Neuropsychology
  • Cognitive Neurology
  • Gerontology

Background:

  • Mild cognitive impairment (MCI) is a transitional stage between normal aging and dementia.
  • Understanding MCI subtypes is crucial for early diagnosis and intervention.
  • The Cardiovascular Health Study (CHS) provided a unique cohort for investigating MCI characteristics.

Purpose of the Study:

  • To delineate the neuropsychological profiles of distinct MCI subgroups.
  • To characterize the amnestic (MCI-AT) and multiple cognitive deficits (MCI-MCDT) types of MCI.
  • To assess the prevalence and cognitive features of MCI subtypes within the CHS cohort.

Main Methods:

  • MCI was classified into amnestic (MCI-AT) and multiple cognitive deficits (MCI-MCDT) types based on specific cognitive criteria.
  • Neuropsychological assessments evaluated memory, language, psychomotor speed, fine motor control, and visuoconstructional abilities.
  • Subjects with systemic, neurological, or psychiatric disorders affecting cognition were excluded.

Main Results:

  • MCI-AT (n=10) demonstrated poorer verbal and non-verbal memory compared to MCI-MCDT (n=28) and controls (n=374).
  • MCI-MCDT exhibited deficits in language, psychomotor speed, fine motor control, and visuoconstructional function.
  • A significant proportion of MCI-MCDT cases (78.5%) had memory deficits, but 21.5% did not, highlighting heterogeneity within this subtype.

Conclusions:

  • MCI-MCDT with memory deficits was the most frequent MCI form observed.
  • Relying solely on memory impairment for MCI identification may underestimate its prevalence, as non-amnestic presentations exist.
  • Investigating both amnestic and non-amnestic MCI forms is vital for understanding MCI etiology.

Related Concept Videos

Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
Cognitive Development During Adulthood01:30

Cognitive Development During Adulthood

Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
Negative and Cognitive Symptoms of Schizophrenia01:30

Negative and Cognitive Symptoms of Schizophrenia

Negative symptoms of schizophrenia indicate a reduction or absence of typical behaviors and emotional responses found in healthy individuals, while positive symptoms reflect an excess or distortion of normal functioning.
Negative Symptoms
Negative symptoms of schizophrenia manifest as deficits in normal emotional and behavioral functioning, profoundly impacting daily life. Individuals with schizophrenia often display a flat affect, characterized by a near-total absence of emotional expression,...